Application of a mixed type of optimization in the implementation of pharmaceutical development of a dosage form of eye drops based on oligohexamethyleneguanidine hydrosuccinate
- Authors: Shatalov D.O.1, Akhmedova D.A.1, Ivanov I.S.1, Kirillova D.D.1, Koroleva Y.A.1,2, Minenkov D.S.3, Kedik S.A.1
-
Affiliations:
- Russian technological university
- Institute of Pharmaceutical Technologies
- Ishlinsky Institute for Problems in Mechanics RAS
- Issue: Vol 26, No 1 (2024)
- Pages: 35-50
- Section: Research paper
- URL: https://journals.eco-vector.com/1682-7392/article/view/625402
- DOI: https://doi.org/10.17816/brmma625402
- ID: 625402
Cite item
Abstract
This study focused on the implementation of the stages of pharmaceutical development of a dosage form of eye drops based on the branched oligohexamethylene guanidine hydrosuccinate according to discrete and continuous optimization, followed by risk assessment and process validation. Experimental samples were developed, critical process and quality parameters were identified, technological characteristics were measured, parameters were normalized, a forecast was made, confirmatory experiments were conducted, the optimal composition was identified, risks in the production of eye drops were assessed, and partial validation was performed. During the implementation of the stages of pharmaceutical development of eye drops based on branched oligohexamethylene guanidine hydrosuccinate, three optimization cycles (discrete and continuous) were carried out, and the optimal ratio of active and auxiliary components was justified based on the results (branched oligohexamethylene guanidine hydrosuccinate 0.05%, polyvinyl alcohol 1%, phosphate-buffered saline 20%, sodium chloride 0.45%, and purified water up to 100%). After reviewing the technological process considering risk analysis, critical points were identified, and partial validation was performed, and the positive results verified and confirmed the optimal choice at this stage of pharmaceutical development. In general, a mixed type of optimization (discrete and continuous) can be used to implement pharmaceutical developments of eye drops based on branched oligohexamethylene guanidine hydrosuccinate, which is confirmed by a series of experiments and risk assessment, and the partial validation verified the data obtained. Thus, pharmaceutical development is a complex and time-consuming process, and limited functionality does not always allow quick identification of the optimal composition of a drug. As an effective solution for implementing the stages of pharmaceutical development, mathematical modeling methods and various types of optimization can be applied.
Full Text
About the authors
Denis O. Shatalov
Russian technological university
Author for correspondence.
Email: shat-05@mail.ru
ORCID iD: 0000-0003-4510-1721
SPIN-code: 3453-9987
MD, Сand. Sci. (Pharm.), associate professor
Russian Federation, MoscowDiana A. Akhmedova
Russian technological university
Email: diana.akhmedova.123@mail.ru
ORCID iD: 0000-0002-0951-939X
SPIN-code: 4629-8311
assistant
Russian Federation, MoscowIvan S. Ivanov
Russian technological university
Email: ivan.ivanov1994@gmail.com
ORCID iD: 0000-0002-1346-7588
SPIN-code: 1899-6495
Сand. Sci. (Pharm.), researcher
Russian Federation, MoscowDaria D. Kirillova
Russian technological university
Email: kirillova1541@mail.ru
ORCID iD: 0000-0002-3055-1116
SPIN-code: 8996-2103
master’s student
Russian Federation, MoscowYulia A. Koroleva
Russian technological university; Institute of Pharmaceutical Technologies
Email: jukka.hiden@bk.ru
ORCID iD: 0000-0001-8092-1990
SPIN-code: 5517-8014
master’s student
Russian Federation, Moscow; MoscowDmitry S. Minenkov
Ishlinsky Institute for Problems in Mechanics RAS
Email: minenkov.ds@gmail.com
ORCID iD: 0000-0001-6432-8134
SPIN-code: 6424-1334
MD, Сand. Sci. (Phyis.), Сand. Sci. (Math.)
Russian Federation, MoscowStanislav A. Kedik
Russian technological university
Email: kedik@mirea.ru
ORCID iD: 0000-0003-2610-8493
MD, Dr. Sci. (Tech.), professor
Russian Federation, MoscowReferences
- Shilovskikh OV, Ponomarev VO, Kazaykin VN, et al. Bacterial keratitis. Part 1. Epidemiology, etiology, pathophysiology, risk factors, clinic, current aspects of diagnosis. Ophthalmology in Russia. 2023;20(1): 17–23. EDN: BSRWLW doi: 10.18008/1816-5095-2023-1-17-23
- Brzheskiy VV. Modern opportunities for the prevention and treatment of inflammatory eye diseases of an infectious nature in children. Ophthalmology reports. 2019;12(4):57–65. EDN: JQDGEV doi: 10.17816/OVI8917
- Azari AA, Arabi A. Conjunctivitis: a systematic review. J Ophthalmic Vis Res. 2020;15(3):372–395. doi: 10.18502/jovr.v15i3.7456
- Babushkin AE. Local antibiotic therapy of bacterial infectious and inflammatory diseases of the anterior segment of the eye (literature review). Point of view. East-West. 2021. № 2. С. 89–93. EDN: JFYMGR doi: 10.25276/2410-1257-2021-2-89-93
- Ivanov IS, Shatalov DO, Kedik SA, et al. Study of the effect of the pharmaceutical substance branched oligohexamethylene guanidine hydrosuccinate in relation to microorganisms. Antibiotics and Chemotherapy. 2019;64(11-12):8–15. EDN: RRPUIR doi: 10.1016/0235-2990-2019-64-11-12-8-15
- Kornyushko VF, Nikolaeva OM, Panov AV, et al. Quality management of the chemical-technological process for continuous synthesis of pharmaceutical substances of medicinal compounds in flow microreactors. Fine Chemical Technologies. 2021;16(3):252–266. EDN: GRYFHU doi: 10.32362/2410-6593-2021-16-3-252-266
- Ivanov IS. Microfluidic synthesis of hydrosuccinate-oligohexamethyleneguanidine substance and creation of ophthalmic preparation on its basis [dissertation]. Moscow; 2021. 118 p. (In Russ.).
- Shatalov DO. Development and standardization of quality control methods for branched oligohexamethyleneguanidine hydrochloride [dissertation]. Moscow; 2015. 137 p. (In Russ.).
- McDermott RE, Mikulak RJ, Beauregard MR. The basics of FMEA. 2nd edit. New York: Productivity Press; 2009, 90 р.